1. Home
  2. Directory
  3. Maryland
  4. Baltimore
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1427690809

AWEKE YILMA DUBI
Prescription History 1427690809
Nurse Practitioner - Family in Baltimore, MD

NPI Status: Active since October 17, 2019

Contact Information

815 E PRATT ST
BALTIMORE, MD
ZIP 21202
Phone: (571) 275-1061

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for AWEKE YILMA DUBI, an active Family specialist practicing in Baltimore, MD. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 85 documented patient claims. Among these therapy options, the most frequently utilized medication is Humulin N, which accounts for 24 claims alone.

Medication Index

B
G
H
No matching medications currently found on file.

Baqsimi

Generic Formulation: GlucagonSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 189
MD State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.1
Peer Average Days Supply364
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,306.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$608.84

State Avg Cost Per Claim

$549.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

Therapeutic Applications

This medication is the same as your body's own glucagon, a natural substance that raises blood sugar by causing the body to release sugar stored in the liver. It is used to treat very low blood sugar (hypoglycemia) that may cause you to need help from others. Make sure a family member or caregiver knows where you keep this medication and how to use it before you need their help.

Glipizide

Generic Formulation: GlipizideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 17
30-Day Fills 20.5
Days Supply 600
MD State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills97.6
Peer Average Days Supply2,909
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.3% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $137.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.09

State Avg Cost Per Claim

$11.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.

Therapeutic Applications

Glipizide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. It may also be used with other diabetes medications. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Glipizide belongs to the class of drugs known as sulfonylureas. It lowers blood sugar by causing the release of your body's natural insulin.

Humulin 70/30 Kwikpen

Generic Formulation: Insulin Nph Hum/Reg Insulin HmSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 20
30-Day Fills 24.0
Days Supply 610
MD State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills42.4
Peer Average Days Supply1,214
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,190.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$159.53

State Avg Cost Per Claim

$257.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Humulin N

Generic Formulation: Insulin Nph Human IsophaneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 24
30-Day Fills 33.0
Days Supply 920
MD State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills64.0
Peer Average Days Supply1,874
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,652.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$68.86

State Avg Cost Per Claim

$126.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Humulin N Kwikpen

Generic Formulation: Insulin Nph Human IsophaneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 19.5
Days Supply 551
MD State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills50.2
Peer Average Days Supply1,480
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,176.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$98.00

State Avg Cost Per Claim

$181.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like AWEKE YILMA DUBI provides transparency into local medical care patterns within Baltimore, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.